Alvin Vitangcol

Alvin Vitangcol

General Partner

Alvin Vitangcol serves as the General Partner for the Capital Midwest Fund.

Alvin has 18 years of experience in venture capital and investment banking transactions. Mr. Vitangcol currently serves on the board for CMF’s investments in CytoPherx and OPS Solutions, and also served as a board director for Sierra Oncology (NASDAQ: SRRA) [fka ProNAi Therapeutics (NASDAQ: DNAI)] and a board observer for PrevaCept Infection Control (fka Great Lakes Pharmaceuticals). Previously as part of Einhorn Associates, he was the primary analyst for a number of M&A transactions and private placements, including the financing of Fulcrum Pharmaceuticals, which merged with Ception Therapeutics, and was subsequently acquired by Cephalon for $350 million with additional potential milestone payments. Mr. Vitangcol’s education includes an MS in Management (emphasis in eBusiness) with honors from the University of Wisconsin – Milwaukee, a BS in Sociology with honors from Andrews University, and a diverse educational background including minors in chemistry, math, and computer science.